Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 6—June 2024
Research Letter

Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan

Akihiro Doi1, Masayuki Ota, Masumichi Saito, and Shutoku MatsuyamaComments to Author 
Author affiliation: National Institute of Infectious Diseases, Tokyo, Japan

Main Article

Figure

Sporadic occurrence of ensitrelvir-resistant SARS-CoV-2 mutants during December 2022–December 2023 in Japan. Solid line indicates the average number of COVID-19 cases. Weekly numbers of SARS-CoV-2 sequences harboring g.10199A>U and g.10199A>C mutations within nonstructural protein 5 were extracted from the GISAID EpiCoV database (https://www.gisaid.org). Number of mutations were aligned on the same time axis as the weekly average number of COVID-19 patients identified at ≈5,000 sentinel hospitals organized by the Japan Ministry of Health, Labor and Welfare. Scales for the y-axes differ substantially to underscore patterns but do not permit direct comparisons.

Figure. Sporadic occurrence of ensitrelvir-resistant SARS-CoV-2 mutants during December 2022–December 2023 in Japan. Solid line indicates the average number of COVID-19 cases. Weekly numbers of SARS-CoV-2 sequences harboring g.10199A>U and g.10199A>C mutations within nonstructural protein 5 were extracted from the GISAID EpiCoV database (https://www.gisaid.org). Number of mutations were aligned on the same time axis as the weekly average number of COVID-19 patients identified at ≈5,000 sentinel hospitals organized by the Japan Ministry of Health, Labor and Welfare. Scales for the y-axes differ substantially to underscore patterns but do not permit direct comparisons.

Main Article

1Current affiliation: ACEL Inc., Kanagawa, Japan.

Page created: April 08, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external